Mohammad Ahmadvand
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Mohammad Ahmadvand has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Mohammad Vaezi
Cell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran
3 shared publicationsAhmadreza Mofayezi
ReNAP Therapeutics, Tehran, Iran; Department of Biotechnology, University of Tehran, Tehran, Iran
2 shared publicationsHossein Salehi-Shadkami
ReNAP Therapeutics, Tehran, Iran; Department of Medical Science, Tehran University of Medical Sciences, Tehran, Iran
2 shared publicationsMaryam Barkhordar
Cell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran
2 shared publicationsMasoumeh Alimohammadi
ReNAP Therapeutics, Tehran, Iran
2 shared publicationsMohammad Sadra Modaresi
ReNAP Therapeutics, Tehran, Iran
2 shared publications
Latest Publications
- 17 December 2025
- Published by Elsevier in Current Research in Translational Medicine
- Vol. 74 (1) , 103563
Lipid nanoparticle mediated delivery of Anti-CD19 CAR mRNA to umbilical cord blood NK cells for targeting CD19⁺ primary B-ALL cells
- 17 December 2025
- Published by Elsevier in Current Research in Translational Medicine
- Vol. 74 (1) , 103563
Lipid nanoparticle mediated delivery of Anti-CD19 CAR mRNA to umbilical cord blood NK cells for targeting CD19⁺ primary B-ALL cells
- Open Access
- 4 June 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1004
Reduced Cish expression by siRNA knockdown in Natural Killer cells promotes anti-tumor effects against gastric cancer cell lines
Improving immune cell functions in tumors remains a main challenge in cancer immunotherapy. NK are main innate effector cells with anti-tumor activity against various tumors. Consequently, NK cells are proper candidates for cancer immunotherapy, including gastric cancer. The IL-15 signaling pathway is negatively regulated by a protein called Cish encoded by the Cish gene. In the present study, we explored the knockdown of Cish and anti-tumor effects of NK cells. We knockdown Cish in human primary NK cells using siRNA, and the expression of Cish was evaluated by qRT-PCR. Gene expression analysis revealed that Cish expression increased after induction by IL-15 at various time point and conversely decreased after knockdown, approximately 44% and 41% reduction were observed at siRNA concentrations of 100 nmol/l at timepoint of 6h and 48h, respectively. Cish knockdown of human NK cells, showed enhanced the anti-tumor effects and induced apoptosis against a human gastric cancer cell lines called MKN-45 and AGS. Additionally, co-culture with MKN-45 and AGS cells showed increased secretion of IFN-γ and TNF-ɑ that could be related to higher cytotoxicity of knockdown Cish NK cells. Our results indicate that Cish knockdown human NK cells enhanced cytotoxicity and cytokine production when co-cultured with gastric cancer cell lines. siRNA-mediated Cish knockdown NK cells, might be a promising immunotherapeutic alternative in patients with gastric cancer.
- 4 June 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1004
Open AccessReduced Cish expression by siRNA knockdown in Natural Killer cells promotes anti-tumor effects against gastric cancer cell lines
Improving immune cell functions in tumors remains a main challenge in cancer immunotherapy. NK are main innate effector cells with anti-tumor activity against various tumors. Consequently, NK cells are proper candidates for cancer immunotherapy, including gastric cancer. The IL-15 signaling pathway is negatively regulated by a protein called Cish encoded by the Cish gene. In the present study, we explored the knockdown of Cish and anti-tumor effects of NK cells. We knockdown Cish in human primary NK cells using siRNA, and the expression of Cish was evaluated by qRT-PCR. Gene expression analysis revealed that Cish expression increased after induction by IL-15 at various time point and conversely decreased after knockdown, approximately 44% and 41% reduction were observed at siRNA concentrations of 100 nmol/l at timepoint of 6h and 48h, respectively. Cish knockdown of human NK cells, showed enhanced the anti-tumor effects and induced apoptosis against a human gastric cancer cell lines called MKN-45 and AGS. Additionally, co-culture with MKN-45 and AGS cells showed increased secretion of IFN-γ and TNF-ɑ that could be related to higher cytotoxicity of knockdown Cish NK cells. Our results indicate that Cish knockdown human NK cells enhanced cytotoxicity and cytokine production when co-cultured with gastric cancer cell lines. siRNA-mediated Cish knockdown NK cells, might be a promising immunotherapeutic alternative in patients with gastric cancer.
- Open Access
Effective targeting of CD19 positive primary B-ALL cells using CAR-NK cells generated with mRNA-LNPs
1. Chimeric antigen receptor natural killer (CAR-NK) cell therapy is recognized as a promising modality for the treatment of hematologic malignancies, particularly B-cell malignancies. In this study, we developed “off-the-shelf” anti-CD19 CAR-NK cells using anti-CD19 CAR mRNAs formulated in proprietary ionizable lipid nanoparticles (LNPs). The efficiency of mRNA-LNP delivery into umbilical cord blood (UCB)-derived NK cells and primary T cells was evaluated in an in-vitro setting, demonstrating superior delivery efficiency in NK cells. Further investigation showed a probable role for an endocytic mechanism, macropinocytosis, in efficient transfection of NK cells with LNPs. Nevertheless, CAR-NK cells generated through this mRNA-LNP platform exhibited significantly enhanced cytotoxicity against CD19 + target cells, such as EGFP + Raji stable cell line and primary malignant B cells derived from refractory/relapsed B-cell acute lymphoblastic leukemia (B-ALL) patients. These findings highlight the promise of the mRNA-LNP platform in advancing CAR-NK therapies against B-cell malignancies.
Open AccessEffective targeting of CD19 positive primary B-ALL cells using CAR-NK cells generated with mRNA-LNPs
1. Chimeric antigen receptor natural killer (CAR-NK) cell therapy is recognized as a promising modality for the treatment of hematologic malignancies, particularly B-cell malignancies. In this study, we developed “off-the-shelf” anti-CD19 CAR-NK cells using anti-CD19 CAR mRNAs formulated in proprietary ionizable lipid nanoparticles (LNPs). The efficiency of mRNA-LNP delivery into umbilical cord blood (UCB)-derived NK cells and primary T cells was evaluated in an in-vitro setting, demonstrating superior delivery efficiency in NK cells. Further investigation showed a probable role for an endocytic mechanism, macropinocytosis, in efficient transfection of NK cells with LNPs. Nevertheless, CAR-NK cells generated through this mRNA-LNP platform exhibited significantly enhanced cytotoxicity against CD19 + target cells, such as EGFP + Raji stable cell line and primary malignant B cells derived from refractory/relapsed B-cell acute lymphoblastic leukemia (B-ALL) patients. These findings highlight the promise of the mRNA-LNP platform in advancing CAR-NK therapies against B-cell malignancies.